SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India. Hagens Berman is investigating poss...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You ma...
PITTSBURGH , March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m.
SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India.
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India. Hagens Berman is investigating poss...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.